X

Trial Profile

A Clinical Study to Evaluate the Safety and Effectiveness of CD19-CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CD19-BCMA-chimeric-antigen-receptor-T-cell-therapy-Shanghai-Ultra-T-Immune Therapeutics (Primary) ; Cyclophosphamide; Fluorine compounds
Indications B-cell lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

26 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Oct 2025.
26 Dec 2023 Planned primary completion date changed from 31 Dec 2021 to 31 Oct 2024.
22 Jan 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com